64P Neoadjuvant toripalimab plus chemotherapy in patients with potentially resectable non-small cell lung cancer: A prospective, single-arm, phase II trial (Renaissance Study)

S Yan,J Chen,J Wang,C Lv,J Bi,X Yang,S Li,Y Wang,X Li,Y Yang,N Wu

doi:10.1016/j.annonc.2021.10.082

64P Neoadjuvant toripalimab plus chemotherapy in patients with potentially resectable non-small cell lung cancer: A prospective, single-arm, phase II trial (Renaissance Study)

S Yan, J Chen + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2021.10.082

Copy DOI

Journal: Annals of Oncology	Publication Date: Dec 1, 2021
Citations: 2	License type: publisher-specific-oa

Affiliation: Peking University Cancer Hospital

#Resectable Non-small Cell Lung Cancer #Combination Of Immune Checkpoint Inhibitor + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Treatment combination of immune checkpoint inhibitor (ICI) and platinum-based chemotherapy have displayed promising anti-tumor activities in resectable non-small cell lung cancer (NSCLC). We designed a phase II trial to elucidate the safety and feasibility of toripalimab (a PD-1 inhibitor) plus double platinum-based chemotherapy as neoadjuvant treatment for potentially resectable NSCLC.

Full Text